Option chain shows key data for Redhill Biopharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) Stock, Option Chain

Redhill Biopharma

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

Screenshot 2025-02-25 at 7.29.32 PM

Biotech

General

RDHL

RedHill Licenses RHB-102 Worldwide Excluding North America To Hyloris For Up To $60M In Potential Milestone Payments Plus Royalties

Screenshot 2025-02-04 at 6.43.58 PM

BAYRY

New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill&#39;s Opaganib And Bayer&#39;s Darolutamide, To Overcome Androgen Resistance

Screenshot 2024-12-05 at 6.50.09 PM

News

Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma Ltd

Press Releases

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill's Opaganib And Bayer's Darolutamide, To Overcome Androgen Resistance

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Earnings

Small Cap

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

Artelo Biosciences

Aytu BioPharma

CNS Pharma

Enveric Biosciences

Evoke Pharma

Eyenovia

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

Impact BioMedical

Jaguar Health

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

cbdMD

Screenshot 2024-10-14 at 5.39.36 PM

RedHill Biopharma Secures U.S. Government Funding Through BARDA To Advance Opaganib For Ebola Treatment

Screenshot 2024-08-22 at 5.32.58 PM

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Comments

Redhill Biopharma

Redhill Biopharma (RDHL) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga